Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Target Price at $134.30

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $134.30.

ORKA has been the subject of a number of research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, April 30th. Guggenheim restated a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $101.82 on Wednesday. The firm’s 50-day moving average is $93.17 and its two-hundred day moving average is $66.41. Oruka Therapeutics has a 12 month low of $14.34 and a 12 month high of $115.51. The stock has a market capitalization of $6.74 billion, a P/E ratio of -50.16 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, analysts anticipate that Oruka Therapeutics will post -2.27 EPS for the current year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, Director Carl Dambkowski sold 22,417 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.13, for a total transaction of $1,572,104.21. Following the sale, the director directly owned 51,326 shares in the company, valued at $3,599,492.38. This represents a 30.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.28, for a total transaction of $550,568.16. Following the sale, the insider directly owned 32,718 shares in the company, valued at $2,266,703.04. This represents a 19.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 83,116 shares of company stock valued at $6,636,533. Insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently added to or reduced their stakes in ORKA. Algert Global LLC raised its stake in shares of Oruka Therapeutics by 3.5% in the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after acquiring an additional 180 shares in the last quarter. Nykredit A S acquired a new position in Oruka Therapeutics during the 2nd quarter worth $29,000. Royal Bank of Canada grew its stake in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in Oruka Therapeutics by 0.9% during the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after purchasing an additional 420 shares during the period. Finally, AlphaCentric Advisors LLC increased its holdings in Oruka Therapeutics by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after purchasing an additional 626 shares during the period. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.